Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.
Read original article on NYT > Science →Related news
-
Green, pink and purple: Astronomers reveal the surprising true colors of white dwarf stars
-
Researchers in exile thrive in new academic settings when they contribute knowledge, not just receive aid
-
One-third of food is lost or wasted: How to help farmers cut postharvest losses
-
NASA develops batteries to power humanity's return to moon
-
Dog that hunts invasive 'sea vomit' honoured as animal of the year
-
India and China aren't friends - but Nepal wants to unite them against climate threats
-
Uganda's sugarcane boom leaves families hungry: What needs to change
-
Fine particles from aircraft exhaust become more harmful over time, lab tests suggest